ReviewJournal of clinical and experimental hematopathology : JCEH2019
Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients.
Review in Journal of clinical and experimental hematopathology : JCEH, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Methotrexate-associated Lymphoproliferative Disorder Showing Colon and Liver Lesions Difficult to Distinguish from Colon Cancer with Liver Metastases.Internal medicine (Tokyo, Japan) · 2026Article
- Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with Pembrolizumab.Internal medicine (Tokyo, Japan) · 2025Article
- Hepatic methotrexate-associated lymphoproliferative disease: a case report and literature review.Surgical case reports · 2024Article
- Epstein-Barr virus-positive mucocutaneous ulcer resulting in severe methotrexate intoxication: a case report.Journal of medical case reports · 2024Article
- A case of methotrexate-related lymphoproliferative disease showing multiple liver lesions in a patient with rheumatoid arthritis.Clinical journal of gastroenterology · 2024Article
- Analysis of Notch1 protein expression in methotrexate-associated lymphoproliferative disorders.Journal of clinical and experimental hematopathology : JCEH · 2024Article
- Copy Number Analysis of 9p24.1 in Classic Hodgkin Lymphoma Arising in Immune Deficiency/Dysregulation.Cancers · 2024Article
- The first case of methotrexate-associated lymphoproliferative disorder in the sacrum: a case report.BJR case reports · 2024Article
- EBV-positive mucocutaneous ulcer arising in methotrexate-treated rheumatoid arthritis patients: a clinicopathological study of 12 cases with analysis of PD-L1 expression.Journal of clinical and experimental hematopathology : JCEH · 2023Article
- Article
- Review
- Methotrexate-Associated Lymphoproliferative Disorder in a Patient with Psoriasis: A Case Report and Review of the Literature.Case reports in hematology · 2022Article
- PD-L1 expression is associated with the spontaneous regression of patients with methotrexate-associated lymphoproliferative disorders.Cancer medicine · 2022Article
- Small intestinal follicular lymphoma induced by methotrexate: a case report.BMC gastroenterology · 2021Article
- Cessation of methotrexate and a small intestinal resection provide a good clinical course for a patient with a jejunum perforation induced by a methotrexate-associated lymphoproliferative disorder: a case report.World journal of surgical oncology · 2021Article
- Methotrexate-associated Lymphoproliferative Disorder in the Liver Resembling Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.Internal medicine (Tokyo, Japan) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methotrexate (MTX) is known as a first-line synthetic disease-modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Although the risk of LPD development increases by RA inflammation itself, observation of spontaneous regression of LPD after MTX discontinuation lead to the theory of lymphomagenic role of MTX. In this review, we focused on the several immune response involved in LPD that developed under MTX administration in RA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.